Table 1.
Demographic and clinical characteristics of EBV patients in the in vitro cohort at baseline.
| EBV CF+ | EBV CF- | Healthy controls (HC) | ANOVA | Post-Hoc | |
|---|---|---|---|---|---|
| n | 32 | 36 | 20 | ||
| Male/female | 4/28 | 16/20 | 6/14 | 0.016* | |
| Age, years | 16.7 ± 1.5 | 16.7 ± 1.5 | 17.8 ± 1.8 | 0.016 | CF+,CF-<HC |
| Days from symptoms | 28.7 ± 5.9 | 32.0 ± 5.8 | 0.027** | ||
| Antibodies | |||||
| EBV VCA IgM titer | 120.1 ± 51.3 | 120.0 ± 51.5 | 1.4 ± 0.4 | <0.001 | CF+,CF->HC |
| EBV VCA IgG titer | 92.3 ± 80.6 | 78.8 ± 34.2 | 81.9 ± 89.2 | ns | |
| EBNA IgG titer | 1.0 ± 4.9 | 1.53 ± 6.2 | 175.3 ± 228 | <0.001 | CF+,CF-<HC |
| Microbiology | |||||
| Blood PCR copies | 1315 ± 1742 | 878 ± 933 | 199 ± 274 | 0.008 | CF+,CF->HC |
| Throat swab PCR +/- | 26/3 | 32/2 | 5/15 | <0.001* | |
| Lymphocytes and subsets | |||||
| Lymphocytes, 109 cells/L | 2.50 ± 1.0 | 2.32 ± 0.7 | 1.79 ± 0.4 | 0.006 | CF+,CF->HC |
| CD4+, 106 cells/L | 885 ± 282 | 799 ± 235 | 780 ± 194 | ns | |
| CD8+, 106 cells/L | 1022 ± 585 | 893 ± 346 | 483 ± 146 | <0.001 | CF+,CF->HC |
| CD19, 106 cells/L | 181 ± 90 | 210 ± 106 | 233 ± 58 | ns | |
| B-cell subpopulations (%) | |||||
| Naive | 80.8 ± 7.3 | 81.5 ± 7.5 | 77.7 ± 7.6 | ns | |
| Transitoric | 4.9 ± 2.9 | 5.8 ± 3.4 | 2.5 ± 1.7 | <0.001 | CF+,CF->HC |
| IgM memory | 8.4 ± 2.9 | 8.6 ± 4.7 | 10.9 ± 3.5 | ns | |
| T-cell subpopulations (%) | |||||
| CD4+ naive | 61.4 ± 10.6 | 60.7 ± 11.6 | 62.5 ± 10.0 | ns | |
| CD4+ memory | 47.8 ± 10.3 | 51.5 ± 11.8 | 52.2 ± 10.6 | ns | |
| CD8+ naive | 57.0 ± 12.9 | 60.0 ± 13.5 | 75.0 ± 15.2 | <0.001 | CF+,CF-<HC |
| CD8+ early eff mem | 29.7 ± 12.0 | 26.8 ± 10.5 | 10.0 ± 3.3 | <0.001 | CF+,CF->HC |
| CD8+ late eff mem | 7.18 ± 5.2 | 7.0 ± 5.5 | 12.7 ± 13.1 | 0.025 | CF+,CF-<HC |
| NK-cell function (%) | 25.8 ± 7.3 | 27.8 ± 7.7 | 23.4 ± 7.5 | n.s | |
Continuous data are given as mean ± SD. ns, not significant. *Chi square test. **T-test.